OCALA, Fla., Oct. 17, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC (“Azenova”), a professional business development (BD) consulting firm, to support efforts to partner AIM’s pipeline programs with a particular focus on the company’s lead…Read More
AIM ImmunoTech Engages Business Development Firm Azenova LLC to Catalyze Partnering Development and Commercialization Efforts for Ampligen Pipeline Programs
